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PEMBANGUNAN GARIS PANDUAN DOS WARFARIN TEMPATAN 
BERASASKAN FARMAKOGENOMIK DAN PENANDA-PENANDA HEMOSTASIS 
 
ABSTRAK 
Warfarin merupakan antikoagulan oral utama yang mempunyai indeks terapeutik yang 
sempit dan perbezaan dos antara individu yang luas, menyebabkan kerumitan pengekalan 
dos optimumnya untuk setiap individu. Banyak model pengedosan warfarin telah 
dibangunkan di seluruh dunia bertujuan untuk menambahbaik ketepatan kaedah pengedosan 
nisbah ternormal antarabangsa (INR) yang digunakan sekarang. Walau bagaimanapun, 
model-model pengedosan berkenaan tidak praktikal untuk digunakan kerana memerlukan 
banyak data tambahan untuk pengiraan dos. Di dalam kajian ini, sebuah model pengedosan 
warfarin untuk populasi tempatan yang lebih mudah telah dikaji untuk permulaan semula 
rawatan warfarin berasaskan data klinikal, makmal dan genetik. 
 Sejumlah 130 pesakit telah direkrut daripada Hospital Universiti Sains Malaysia 
untuk pembinaan model tersebut. Data klinikal pesakit diambil daripada pengkalan data 
hospital. Kaedah tindak balas berantai polimerase - polimorfisme pemotongan panjang 
cebisan (PCR-RFLP) telah digunakan untuk penjenisan CYP2C9*2, *3 dan VKORC1 -
1639G>A, manakala sebuah kaedah PCR multipleks spesifik alel tersarang yang baharu 
dibangunkan telah digunakan untuk penjenisan VKORC1 381, 861, 5808 dan 9041.  Data-
data genotip VKORC1 381, 861, 5808 dan 9041 telah digunakan untuk mengiferensikan 
haplotip VKORC1. Aktiviti faktor koagulasi II, VII, IX dan X bergantung vitamin K (VKD) 
telah diukur dengan menggunakan mesin penganalisis hemostatik. Sebuah kaedah baharu 
kromatografi cecair berprestasi tinggi (HPLC) dengan pengesan UV dibangunkan dan 
disahkan untuk digunakan bagi mengukur aras warfarin serum yang kemudiannya digunakan 
untuk pengiraan data farmakokinetik di dalam 24 orang pesakit. Model pengedosan warfarin 
telah dibangunkan dengan menggunakan kaedah regresi linear berbilang ke depan. 
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 Genotip CYP2C9*2 dan *3 mutan heterozigot adalah jarang (kedua-duanya dengan 
kekerapan 3.8%), manakala genotip mutan homozigot langsung tidak dikesan. Kekerapan 
VKORC1 -1639G>A dan VKORC1 381 adalah sama. Genotip dengan kekerapan paling 
tinggi adalah genotip yang berkeperluan dos warfarin rendah (GG: 54.6%). VKORC1 H1H1, 
H1H7 atau H1H9 dan H7H7 adalah pasangan-pasangan haplotip yang paling lazim (53.1, 
32.5 dan 10.0%). Kesemua aktiviti faktor koagulasi VKD tidak berhubungkait secara ketara 
dengan keperluan dos warfarin INR. Kepekatan maksimum serum, separuh hayat dan 
pembersihan warfarin tidak berhubungkait secara ketara dengan mana-mana data genetik 
atau keperluan dos warfarin. Model pengedosan warfarin muktamad adalah terdiri daripada 
umur, jumlah alel VKORC1 381, min INR dan sejarah penggantian injap mitral sebagai 
faktor-faktor peramal. Faktor-faktor peramal tersebut dapat menerangkan 45.6% 
kebolehubahan dos warfarin.  
 Model pengedosan yang dibangunkan adalah sesuai untuk digunakan sebagai garis 
panduan untuk menentukan dos warfarin pesakit yang memerlukan permulaan semula 
rawatan warfarin.   
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DEVELOPMENT OF A LOCAL WARFARIN DOSAGE GUIDELINE BASED ON 
PHARMACOGENOMICS AND HAEMOSTATIC MARKERS 
 
ABSTRACT 
Warfarin, the mainstream oral anticoagulant, has a narrow therapeutic index and wide 
interindividual dose variability, rendering maintaining its optimal dose in each individual a 
difficult task. Many warfarin dosing models have been developed worldwide in order to 
improve the accuracy of currently used international normalised ratio (INR) dosing method. 
However, those dosing models were not practical to be used due to extensive additional data 
that are required for dose calculation. In this study, a simpler warfarin's dosing model for 
local population has been studied for warfarin therapy reinitiation based on clinical, 
laboratory and genetic data. 
 A total of 130 of patients on warfarin treatment in Hospital Universiti Sains 
Malaysia were recruited for the model-building. Patients' clinical data were extracted from 
the hospital database. Polymerase chain reaction - restriction fragment length polymorphism 
(PCR-RFLP) methods were used for genotyping of CYP2C9*2, *3 and VKORC1 -1639G>A 
while a newly developed nested allele-specific multiplex PCR was used for genotyping of 
VKORC1 381, 861, 5808 and 9041. Genotype data of VKORC1 381, 861, 5808 and 9041 
were used to infer VKORC1 haplotype. The activity of vitamin K-dependent (VKD) clotting 
factors II, VII, IX and X were measured by using a benchtop haemostatic analyser. A newly 
developed and validated high performance liquid chromatography (HPLC) method with UV 
detector was used for measurement of serum warfarin levels that were subsequently used for 
pharmacokinetics data calculation in 24 patients. The warfarin's dosing model was developed 
by using a forward multiple linear regression. 
 The heterozygous mutant genotype of CYP2C9*2 and *3 were rare (both at 3.8%), 
while the homozygous mutant was not detected. The frequency of VKORC1 -1639G>A and 
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VKORC1 381 were similar. The genotype with highest frequency was the low warfarin's 
dose requirement genotype (GG: 54.6%). The VKORC1 H1H1, H1H7 or H1H9 and H7H7 
were the most common haplotype pairs (53.1, 32.5 and 10.0%). All VKD clotting factor 
activities were not significantly associated with warfarin's dose requirement or with the INR. 
Maximum serum concentration, half-life and clearance of warfarin were not significantly 
associated with any genetic data or warfarin's dose requirement. The final warfarin's dosing 
model consists of age, the number of VKORC1 381 allele, mean INR and history of mitral 
valve replacement as useful predictor factors. The predictor factors explained 45.6% of 
warfarin dose variability. 
 The developed dosing model is suitable to be used as guideline to determine the 
warfarin dose of patients who need to reinitiate a warfarin therapy. 
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CHAPTER 1  
INTRODUCTION 
1.1 Anticoagulation treatment 
Warfarin is an oral anticoagulant prescribed to patients to prevent pathological blood clot in 
circulation, also known as thrombosis. Thrombosis can impose life-threatening  health risks 
such as stroke and pulmonary embolism (PE). However, warfarin has a narrow therapeutic 
window in which insufficient dose will fail to protect the patient from the disease, while 
excessive dose can expose patients to uncontrolled bleeding. Therefore, patients are expected 
to adhere to the prescription and comply with a lower vitamin K diet to prevent food-
warfarin interaction. Besides food, concomitant medications, supplements and the presence 
of other risk factors such as liver impairment and fever can also affect warfarin's sensitivity 
(Demirkan et al., 2000). Once warfarin is prescribed, the patients are required to regularly 
visit healthcare providers in order to re-adjust warfarin's dose according to the lifestyle 
changes. 
 Although several novel oral anticoagulants require less frequent dose adjustment and 
show minimum food-drug interactions such as dabigatran, rivaroxaban and apixaban are 
already commercially available and are superior (or at least not inferior) in their therapeutic 
outcomes (Ahrens et al., 2011). Warfarin still remains as the mainstay oral anticoagulant due 
to its cheaper cost and established use especially in the event of overdose. 
 Nevertheless, dosing of warfarin is not simple because although warfarin is given 
according to the dosing guideline and patients comply to the therapy, overdosing still occur 
rather frequently. Numerous studies have indicated that genetic polymorphisms affect the 
pharmacokinetics and pharmacodynamics of warfarin (Yin and Miyata, 2007; Kamali and 
Wynne, 2010) thereby rendering patients to be either resistant or sensitive to warfarin 
treatment. Since warfarin is likely to be incorporated in the clinical settings for years to come, 
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a better understanding on how genetic polymorphism are associated with warfarin's 
sensitivity is needed. It is hoped that the integration of genetic data and other coagulation 
markers into pre-existing warfarin dosing guidelines may improve dosing accuracy thereby 
reducing adverse effects.  
 
1.2 Thrombosis and thromboembolism  
1.2.1 Definition 
Blood is a dynamic body fluid which carry various gasses, nutrients, hormones and chemical 
compounds throughout the body. Escape of blood from the blood vessel need to be 
immediately stopped to avoid uncontrolled haemorrhage. It has been reported that human 
can sustain up to 20% of blood loss before experiencing a hypovolaemic shock and getting 
the risk of reperfusion injury (Mannucci and Levi, 2007; Shults et al., 2008). When the blood 
vessel is exposed to injury, haemostasis is triggered in which platelet can initiate plasma plug 
formation to temporarily seal the ruptured blood vessel. Meanwhile, a coagulation cascade 
will start in which the clotting factors will undergo a series of activations to form blood clot 
at the injury site to prevent the outflow of blood from the blood vessel. The clot formation is 
regulated by naturally occurring anticoagulants (antithrombin III, protein C and protein S) to 
contain the clot to only within the vicinity of the injured blood vessel (High, 1988). 
 However, in the presence of a pathological condition, thrombus can block the blood 
flow to vital organs which can lead to hypoxia and eventually becomes necrotic. The 
formation of thrombosis in the artery vary from that in the vein (Previtali et al., 2011). 
Arterial thrombosis is usually an outcome of atherosclerosis. The arterial thrombus, also 
known as white thrombus, mainly consists of white blood cells and platelets with cardiac 
muscle being one of the most commonly affected organ. Decreased oxygen supply to cardiac 
muscles can cause ischaemic heart disease (IHD) and eventually leads to myocardial 
infarction (MI), while thrombosis in brain artery can cause stroke. On the other hand, venous 
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thrombosis leads to venous thromboembolism (VTE), where the thrombus itself may 
dislodge from its original site and travel throughout the circulation as an embolus. The most 
common VTE is deep vein thrombosis (DVT), where the thrombus is usually formed in the 
leg veins. The venous thrombus, also known as red thrombus, mainly consist of red blood 
cells and fibrin. The dislodged embolus from the DVT may stop at the lung blood vessel and 
lead to PE. 
1.2.2 Pathogenesis 
Arterial and venous thrombosis have different pathogenesis and risk factors (Table 1.1). In 
the artery, the thrombus is mainly formed following atherosclerosis. Atherosclerosis is 
thickening of the artery wall due to the accumulation of monocytes, macrophages, dead cells, 
cholesterol, calcium and fibrous tissues within the arterial endothelium. One of the major 
risk factors of atherosclerosis is the presence of metabolic syndrome (Glasser et al., 1996). 
Individuals with metabolic syndrome are characterised by high level of low-density 
lipoprotein (LDL), low level of high-density lipoprotein (HDL), hypertension, 
hyperglycaemia and abdominal obesity (Paoletti et al., 2006). Collectively, these disorders 
exacerbate the intrusion of macrophages beneath the blood vessel, induce endothelial 
dysfunction by reducing the level of indigenous vasodilator nitric oxide (NO) (Mehta et al., 
2001), produce pro-inflammatory cytokines (Zhu et al., 2005; Fernández-Sánchez et al., 
2011) and cell adhesion mediators (Zeiher et al., 1995), increase oxidative stress on the 
artery (Cosentino et al., 1997; Guzik et al., 2002) ultimately leading to atherosclerosis. 
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Table 1.1: Risk factors of arterial and venous thrombosis 
Arterial Venous 
Virchow's triad Contemporary categories 
Metabolic syndrome Blood flow stasis Acquired 
• High LDL level • Immobilisation • Ageing 
• Low HDL level • Left atrial appendage coagulation o Hospitalisation 
• Hyperglycaemia • Left ventricular dilatation o Dysfunctioned endothelium 
• Hypertension • Mitral valve stenosis o Venous insufficiency 
• Abdominal obesity Epithelial injury o CHF 
Smoking • Trauma o COPD 
Male • Endothelial inflammation o Increase levels of clotting factors 
Cardiac disorders • Infection o Increase levels of fibrinolysis inhibitors  
• AF Abnormal blood constituent • Previous thrombosis 
• Valvular diseases • Abnormal platelet level • Immobilisation 
o Ageing • Abnormal globulin level • Major surgery 
o Rheumatic disease • Abnormal fibrinogen level • Oral contraceptive 
o Endocarditis • Abnormal calcium level • Hormone replacement therapy 
o Congenital heart defect • Dehydration • Antiphospholipid syndrome 
• Prosthetic heart valve • Pregnancy • Myeloproliferatide disorders 
 • Infection • Cancer 
 • Obesity • Pregnancy 
  Inherited 
  • Decrease expression of antithrombin III 
  • Decrease expression of protein C and S 
  • Factor V Leiden G1691A mutation 
  • Prothrombin G202010 mutation 
  Mixed 
  • Ageing with clotting factor genes mutation 
  • Hyperhomocysteinaemia 
 
LDL = low-density lipoprotein; HDL =  high-density lipoprotein; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease
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 Smoking is a non-metabolic syndrome risk factors of atherosclerosis. Nicotine in 
tobacco smoke can induce arterial stiffness besides elevating plasma LDL level while 
lowering plasma HDL levels (Powell, 1998; Villablanca et al., 2000). Male individuals also 
have increased predisposition to atherosclerosis when compared with females. In-vitro study 
showed that androgen hormone up-regulate atherosclerosis-related genes in macrophages 
derived from male donors but not in macrophages derived from female donors (Ng et al., 
2003). 
 Non-atherosclerosis-related arterial thromboses caused by cardiac disorders such as 
atrial fibrillation (AF) leads to irregular heart rhythm that promotes stagnant blood flow at 
atrial appendage (GalalAzzam, 2013). Valvular heart diseases especially mitral valve 
stenosis, can cause blood stasis in left atrium (Demir et al., 2001; Misumi et al., 2003; Rost 
et al., 2008). The stagnant blood eventually leads to thrombosis. Therefore, heart valve 
replacement as a consequence of valvular disease, especially the use mechanical prosthetic 
valve, may also increased the risk of thrombosis (Roudaut et al., 2007; Pibarot and Dumesnil, 
2009). 
 Venous thrombosis has different pathogenesis where the thrombus are not formed on 
an atheromatous plaque. Classically, the pathogenesis of venous thrombosis is related to the 
risk factors as described in Virchow's Triad, a postulation that relates thrombogenesis with 
three factors, which are blood flow stasis, epithelial injury and abnormal blood constituent 
(Lip and Gibbs, 1999). Nevertheless, this postulation is obsolete with a new categorical 
system used to classify the risk factors of venous thrombosis. Currently, venous thrombosis 
risk factors are divided into three groups: acquired, inherited and mixed risk factors 
(Rosendaal, 1997). The strongest acquired risk factor for thrombosis is advanced age, caused 
by numbers of elderly-related co-morbidities and increase in level of various plasma proteins 
and clotting factors (Cushman, 2007; Ageno et al., 2008). 
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 The remaining acquired risk factors include exposure to previous thrombosis, 
immobilisation, major surgeries, oral contraceptive-induced activated protein C resistant, 
hormone replacement therapy, antiphospholipid syndrome and myeloproliferative disorders 
(Rosing et al., 2001; Ortel, 2005; Tefferi and Elliott, 2007; Pottier et al., 2009; Healy et al., 
2010). Cancer patients also have a high risk of thrombosis due to the production of tissue 
factor (TF) by affected organs and cancer cells (Prandoni et al., 2005; Hron et al., 2007). 
Pregnancy is also closely related to increased level of thrombosis clotting factors VII, X, and 
VIII, fibrinogen and vWF levels with decreased the natural anticoagulant protein levels. 
(Brenner, 2004). 
 Thrombosis can also be an inherited genetic disorder. Mutations may not only 
decrease the expression of certain naturally occurring anticoagulants such as antithrombin III, 
protein C and protein S (Pabinger et al., 1992), but also cause gain-of-function of certain 
clotting factors. Factor V Leiden G1691A and prothrombin G202010 are the most common 
thrombophilic mutations, which can cause gain-of-function by making factor V able to resist 
Protein C inactivation and upregulating the production of prothrombin, respectively (Bertina 
et al., 1994; Castoldi et al., 2007). It has been reported that family members from a person 
with a history of thrombophilia are more susceptible to thrombosis (Ben-Tal et al., 1989; 
Allaart et al., 1993) and may experience thrombosis in earlier age (Lensen et al., 1996) when 
compared with individuals who do not have such family history. 
 Non-genetic risk factors may also play a role in thrombosis along with genetic 
factors. Although there are evidences that increased levels of clotting factors VIII, IX, XI 
and fibrinogen are familial disorders (Lane and Grant, 2000; Jenkins et al., 2012), other 
factors like ageing and inflammation also contribute to thrombogenesis (Previtali et al., 
2011). Hyperhomocysteinaemia, a disorder that cause endothelial dysfunction, is contributed 
by both genetic mutation in methylenetetrahydrofolate reductase gene and deficiency in 
vitamins B12, B6 and folate levels (Selhub and D'Angelo, 1998). 
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 Despite the discrete categories, venous thrombosis is often multicausal. A study 
found that 84% of children with DVT have more than a single risk factor for thrombosis 
(Andrew et al., 1994). Except for some major surgeries and traumas, most single risk factors 
of thrombosis are unlikely to cause thrombosis hence requiring no prophylaxis (Anderson 
and Spencer, 2003). However, the interaction between the risk factors for thrombosis is 
synergistic. For example, individuals with factor V Leiden suffering from leg injury are 50-
fold more likely to develop thrombosis when compared with individuals without both risk 
factors, while individuals with only leg injury and factor V Leiden had only 5 and 6.8-fold 
higher likelihood, respectively (van Stralen et al., 2008).  
 Individuals with congestive heart failure (CHF) are known to be more susceptible to 
thrombosis due to low cardiac output, endothelial dysfunction and increased platelet 
aggregation. However, the thromboembolic outcome of CHF was formerly overlooked due 
to the understanding that the primary mortality in CHF is contributed by a sudden cardiac 
death rather than thrombosis per se (Sosin et al., 2003). The role of CHF as an important risk 
factor for thrombosis was reiterated only after some studies confirmed that CHF patients 
who receive thromboprophylaxis have better outcomes (less mortality, MI and stroke events) 
than patients who do not receive the treatments (Cleland et al., 2004; Cokkinos et al., 2006; 
Massie et al., 2009). 
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1.2.3 Prevalence 
Although heart valve replacement is the main indication for warfarin in other countries 
(White et al., 1996), warfarin is mainly prescribed for AF in Malaysia. The worldwide 
prevalence of AF is reported to be 1.5 - 2.0% (Camm et al., 2012). According to a study 
conducted in an urban hospital in Malaysia, 2.8% from overall acute medication prescription 
was for patients with AF, while 20% of AF patients were on warfarin treatment (Freestone et 
al., 2003). However, oral anticoagulant use among AF patients in Malaysia is lower than that 
in the United States (65.0%) (Kirley et al., 2012) and Europe nations (64.8%) (Pisters et al., 
2010). Nevertheless, warfarin remains the top-ranking antithrombotic drug in Malaysia just 
after aspirin, ticlopidine and clopidogrel (MOH, 2013b). Furthermore, although adverse drug 
reactions from warfarin use in Malaysia is not extensively reported, it cannot be denied that 
warfarin is the top-10 leading drugs which cause adverse effects in United States (Wysowski 
et al., 2007) with the incidence of serious bleeding among patients on warfarin treatment to 
be as high as 16% while 2.9% was reported to be fatal (Da Silva and Sobel, 2002).   
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1.3 Warfarin 
1.3.1 History 
In the early 1920s, a group of farmers in North America reported a strange fatal 
haemorrhagic disease seen among their cattle following consumption of the molded sweet 
clover (Melilotus officinalis) hay (Schofield, 1924). After an investigation, a veterinarian 
named Roderick found that the sweet clover contains an unknown anticoagulant which 
caused 'plasma prothrombin defect' (Roderick, 1929). In 1933, Karl P. Link began an 
investigation to identify the type of the agent present in the sweet clover. Six years later, his 
co-workers successfully isolated the agent and began to synthesise it. The anticoagulant was 
named as dicoumarol (Stahmann et al., 1940; Link, 1959) which inhibits prothrombin, a 
clotting factor in human that plays a main role in the coagulation cascade (Overman et al., 
1941). 
 In 1948, Link introduced a potent analogue of dicoumarol, named warfarin, as a 
commercial rodenticide (Last, 2002). Due to its better potency than dicoumarol, warfarin 
was later proposed as a prophylaxis drug for thromboembolism instead of dicoumarol. In 
1951, a US Army inductee used the rodenticide warfarin in an attempt to commit suicide. 
However, the toxicity effect was not fast enough to kill him instantly and he was 
successfully rescued from fatal haemorrhage after being given vitamin K as an antidote. This 
fateful event convinced clinicians that warfarin is indeed a potent anticoagulant with a 
reliable safety index (Link, 1959). Eventually, warfarin was marketed as Coumadin Sodium 
in 1954 to replace dicoumarol as an oral anticoagulant. 
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1.3.2 Indication and dosing 
Warfarin is used as a prophylaxis for both arterial and venous thromboembolic disorders. 
Patients who have arterial embolism, AF, coagulopathy, DVT, heart valve replacement, MI 
with risk of stroke, PE, pulmonary hypertension and transient ischaemic attack can be given 
warfarin treatment (MOH, 2010; FDA, 2014). 
 Warfarin is contraindicated in patients a) who are pregnant or may becomes 
pregnant b) who recently or are planned for surgery c) who experience threatened abortion d) 
who potentially not compliant [due to senility, alcoholism or psychosis] and d) who are 
recently or planned for spinal puncture  (FDA, 2014). 
 The decision to prescribe warfarin or otherwise is decided by clinician by assessing 
the following bleeding risks (MOH, 2010): age ≥ 65 years, history of stroke, history of 
gastrointestinal bleeding, recent MI, haematocrit level (<30%), creatinine level (>133 
µmol/L) and diabetes.  
 Usually, warfarin is administered to a patient based on an individualised dose. The 
initial dose is usually 5 mg o.d., or 3 mg o.d. in elderly patients, while the subsequent dosage 
from day-3 onwards are adjusted based on International Normalised Ratio (INR), an index 
obtained from laboratory test by using patient's plasma sample. 
INR = ( PTMNPT)ISI 
         (Le et al., 1994) 
 
PT  = Prothrombin time measured from patient's plasma 
MNPT  = Mean normal prothrombin time, measured from a pooled plasma of  
     healthy individuals 
ISI  = International sensitivity index, a coefficient used to measure the sensitivity 
     of thromboplastin provided by the reagent's manufacturer. 
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 Patients on warfarin treatment are expected to achieve a targeted INR (Table 1.2) 
(MOH, 2013a). An INR below the recommended range indicates that the patient receives 
insufficient anticoagulation and therefore warfarin dose should be increased. An INR above 
the recommended range indicates that the patient has received excessive anticoagulation and 
therefore warfarin dose should be decreased. Once the INR is within the recommended range, 
the patient is required to visit the clinic monthly in order to determine the INR again and to 
adjust the dose accordingly. A patient with an INR above 5.0 needs to withhold warfarin 
immediately and receive vitamin K antidote before restarting the treatment with a lower dose 
than the previous one (Gallus et al., 2000). Serious bleeding incident suspected due to 
warfarin treatment in any INR require immediate withholding of warfarin, slow infusion of 
vitamin K and fresh frozen plasma or prothrombin complex concentrate supplement.   
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Table 1.2: Recommended INR ranges (MOH, 2010) 
Indication INR 
AF 2.0 - 3.0 
Bioprosthetic valve replacement 2.0 - 3.0 
Mechanical mitral valve replacement 2.5 - 3.5 
DVT 2.0 - 3.0 
DVT and PE 2.0 - 3.0 
High risk surgical patient 2.5 - 3.5 
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1.3.3 Pharmacokinetics 
Warfarin is a racemic mixture of two enantiomers: (S)- and (R)-warfarin (Figure 1.1) which 
have different pharmacokinetics properties. After oral administration, its bioavailability is 
almost 100%.  The maximum plasma concentration is achieved in 4 hr (FDA, 2014). 
However, the onset of its anticoagulation effect not immediate and is only begins to be 
observable in 36-72 hr (Lexi-Comp, 2014).  
 Warfarin is 99% bound to plasma protein, most of which is human serum albumin, 
while a small fraction binds to human α1-acid glycoprotein (AGP), which is also called as 
orosomucoid (Otagiri et al., 1987). Only 1% of administered warfarin is unbound and 
manifest its therapeutic effect. The protein-bound warfarin is continuously released into the 
plasma once the unbound warfarin is depleted (Wilting et al., 1980).  
 The plasma concentration of (R)-warfarin is 1.5 times higher than the (S)-warfarin at 
steady state (Osman et al., 2005). However, (S)-warfarin is three to five times more potent 
than the (R)-warfarin (O'Reilly, 1974). The relatively small volume of distribution of 
warfarin (0.14 L/kg) (FDA, 2014) conforms with the fact that it is highly plasma protein-
bound and is not extensively distributed into other tissues such as muscles or fats. 
 Warfarin is metabolised by hepatic cytochrome P450 isoenzymes (CYP). 
Metabolism of warfarin is stereoselective, where in phase I metabolism (R)-warfarin is 
metabolised by CYP1A2, CYP3A4, CYP2C8 and CYP2C19 isoenzymes, while (S)-warfarin 
is predominantly metabolised by CYP2C9 isoenzyme (Limdi and Veenstra, 2008). Phase II 
metabolism of warfarin metabolites is by glucuronidation and sulphonation (Jansing et al., 
1992). 
 Even though (S)-warfarin is more potent than (R)-warfarin, it is eliminated faster 
than (R)-warfarin [half-life for (S)-warfarin is 29 hr while that for (R)-warfarin is 45 hr]. 
Elimination of warfarin is mainly through renal excretion (92%), where (S)-warfarin have 
almost three times faster clearance than (R)-warfarin (Hallak et al., 1993).   
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Figure 1.1: (S)-warfarin  (1a) and (R)-warfarin (1b) with different orientation of their 
benzene rings (Li and Robinson, 2001) 
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1.3.4 Pharmacodynamics  
During physiological condition, coagulation occurs when vitamin K-dependent (VKD) 
clotting factors II, VII, IX and X in the circulation are activated by carboxylation (Figure 
1.2). Carboxylation of these VKD clotting factors require vitamin K hydroquinone (reduced 
vitamin K) as a cofactor. Warfarin however, suppresses the activation of the VKD clotting 
factors by inhibiting the recycling of vitamin K hydroquinone (reduced vitamin K) from 
vitamin K epoxide (Fasco and Principe, 1982). The enzyme which is responsible in recycling 
the reduced vitamin K, vitamin K epoxide (VKOR) is inhibited by both (R)- and (S)-
warfarin. However, the latter has higher affinity to VKOR, thus making (S)-warfarin more 
potent than (R)-warfarin (O'Reilly, 1974). Decrease in activation of VKD clotting factors 
leads to decreased fibrin formation, therefore reducing the clotting ability of blood. 
 Each type of activated VKD clotting factors has different half-life before being 
eliminated (O'Reilly and Aggler, 1968). Clotting factor II has the longest half-life (50 hr). 
Warfarin's anticoagulation effect will only manifest after all of the activated VKD clotting 
factors are eliminated from the circulation which explains the slow onset of warfarin after 
the administration of the first dose. However, large warfarin loading dose is not given to 
patient because clotting inhibitors protein C and its precursor protein S also require reduced 
vitamin K for its activation. A sudden decrease in reduced vitamin K can cause warfarin-
induced skin necrosis due to the formation of thrombus beneath the skin (Stewart et al., 
1999). 
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Figure 1.2: Vitamin K cycle and inhibition clotting factors activation by warfarin 
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1.4 Pharmacogenetics aspects 
1.4.1 Cytochrome P450 2C9 genes 
Most drugs are metabolised by cytochrome P450 isoenzymes, including warfarin (Kaminsky 
and Zhang, 1997). Racemic warfarin is metabolised by CYP1A2, CYP2C8, CYP2C9, 
CYP2C19 and CYP3A4 (Limdi and Veenstra, 2008). The genes that encode for these 
isoenzymes are polymorphic. Individuals with polymorphic cytochrome P450 gene may 
have decreased ability to metabolise warfarin and may suffer from adverse drug effect. 
 Due to the evidences that (S)-warfarin is more potent than (R)-warfarin, most 
researchers only investigate the gene the encodes for the isoenzyme that metabolise (S)-
warfarin, which is CYP2C9. CYP2C9*2 retains approximately 12% of the enzymatic activity 
of the wild-type variant, while CYP2C9*3 retains only 5% (Rettie et al., 1994; Haining et al., 
1996). Significant association between CYP2C9*2 and *3 polymorphisms with warfarin's 
dose requirement and bleeding complication have been reported (Aithal et al., 1999; Higashi 
et al., 2002; Hillman et al., 2004; Yildirm et al., 2012). Due to the strong findings on the 
influence of the pharmacogenetics effect of CYP2C9, the recommendation to use CYP2C9 
genetic data was integrated into warfarin dosing label by the FDA starting from 2007 (FDA, 
2007).  
 On the other hand, CYP3A4 is the major isoenzyme which metabolises (R)-warfarin. 
However, a study which investigated the association of CYP3A4 polymorphisms and the 
dose requirement for a warfarin analogue (acenocoumarol) failed to establish any significant 
association (Saraeva et al., 2007). Unlike other cytochrome P450 isoenzymes which 
metabolise warfarin, CYP4F2 is responsible in metabolising reduced vitamin K (McDonald 
et al., 2009). Therefore, individuals with CYP4F2 polymorphism tend to require higher 
warfarin dose due to high level of vitamin K in their body. There are evidences of 
association of CYP4F2 with warfarin's dose requirement (Caldwell et al., 2008; Pautas et al., 
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2010; Perini et al., 2010). Nevertheless, it was finally concluded that the association is not as 
clinically important as CYP2C9 in actual practice (Kringen et al., 2011).  
 
1.4.2 Vitamin K epoxide reductase complex subunit 1 
CYP2C9 was generally accepted as the main genetic determinant for the sensitivity to 
warfarin treatment, until the role of  vitamin K epoxide reductase complex-1 gene (VKORC1) 
polymorphism was extensively investigated. The gene itself was relatively newly discovered 
in 2004 (Li et al., 2004; Rost et al., 2004). Unlike CYP2C9 whose single nucleotide 
polymorphisms (SNP) were located at the coding region, the common human VKORC1 
polymorphisms were at the intronic region, thus affecting the expression of VKORC1 
enzyme instead of changing the conformation of the enzyme. Depending on the type of 
VKORC1 variant, it may render an individual to be more sensitive or resistant to warfarin 
treatment (Table 1.3). 
 Unlike other studies where a single VKORC1 SNP is reported to be independently 
correlated to a phenotype (Carlquist et al., 2006; Caldwell et al., 2007), Rieder and 
colleagues identified 10 SNPs and combined them in a sequence called 'haplotype sequence'. 
Depending on the type of combinations, the haplotype sequences are designated with 
different types of 'haplotype identification code': H1, H2, H7 (for low dose requirement), H8 
and H9 (for high dose requirement). Due to the fact that human DNA allele is double-
stranded, two haplotype identification codes are required to determine the phenotype of an 
individual (Rieder et al., 2005).  
 Stratification of warfarin's sensitivity based on the haplotype method is believed to 
be more accurate than when only a single VKORC1 SNP is used. However, this fact may not 
be true in a population where most of the VKORC1 SNPs are uncommon. It has been 
suggested that identification of only VKORC1 381 alone in an Asian population is sufficient 
to determine whether an individual is resistant or sensitive to warfarin treatment (Lee et al., 
2006). The VKORC1 381 alone were also theoretically useful because it is closely linked to 
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VKORC1 -1639G>A (Rieder et al., 2005), which is the most extensively studied single 
VKORC1 genotype (Sconce et al., 2005; Aquilante et al., 2006; Gan et al., 2012). However, 
a retrospective study which apply this suggestion found that approximately 10% of the study 
population are still inaccurately dosed (Tham et al., 2006). Therefore, haplotyping method 
may still be useful to accurately stratify patients sensitivity to warfarin treatment. 
 In terms of usefulness in predicting sensitivity to warfarin, VKORC1 is considered a 
stronger predictor than CYP2C9. When combined with other data such as age, weight and 
CYP2C9 genotype, VKORC1 is able to explain as high as 68% of the dose variability (Table 
1.4). Along with CYP2C9*2 and *3, VKORC1 -1639G>A genotypic data is therefore 
recommended by the FDA to be used for warfarin's dose determination (FDA, 2007).          
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Table 1.3: VKORC1 SNP variants used by Rieder et al. (2005) to delineate the haplotype of 
sensitivity to warfarin treatment  
Position RefSNP Variant Variant 
Nucleotide Warfarin dose 
requirement 
Nucleotide Warfarin dose 
requirement 
381 rs7196161 T High C Low 
861 rs17880887 C Low A High 
2653 rs17881535 G Low C High 
3673 rs9923231 G High A Low 
5808 rs2884737 T High G Low 
6009 rs17708472 C Low T High 
6484 rs9934438 C High T Low 
6853 rs8050894 G High C Low 
7566 rs2359612 C High T Low 
9041 rs17880624/ 
rs7294 
G High A Low 
 
RefSNP = reference SNP 
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Table 1.4: Application of VKORC1, other genetic and demographic data and their reliability to explained warfarin dose variability  
Investigators % of dosing variability explained when VKORC1 and other 
predictors were used  
% of dose variability explained 
when CYP2C9 alone was used 
Rieder et al. (2005) VKORC1 haplotypes: 25% 
 
CYP2C9 variants: 10.0% 
Bodin et al. (2005)^ VKORC1 -1639G>A: 50% 
 
VKORC1 -1639G>A, CYP2C9 and body weight: 54% 
 
CYP2C9*3: 14.0%  
 
Sconce et al. (2005) Age, height, CYP2C9*2 & *3 and VKORC1 -1639G>A: 
54.2% 
 
CYP2C9 variants: 17.5% 
Veenstra et al. (2005)  VKORC1 genotypes: 31% 
 
CYP2C9 variants: 7.9%. 
Lee et al. (2006) VKORC1 haplotypes: 30% 
 
VKORC1 haplotypes, age, CYP2C9*3, gender and race: 48 % 
 
CYP2C9*3: 29.0% 
Tham et al. (2006) Age, weight, CYP2C9*3, VKORC1 381: 60.2% 
 
CYP2C9*3: 17.5% 
Caldwell et al. (2007) VKORC1 6853 (rs 8050894), CYP2C9*2,*3, age, gender, 
body surface area, history of diabetes, history of heart valve 
replacement: 56% 
 
CYP2C9 variants: 28.2% 
   
^ The study was to observes the effect of VKORC1 SNPs on acenocoumarol. 
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Table 1.4 (Continued) 
 
Investigators % of dose variability explained when VKORC1 and other 
predictors were used  
% of dose variability explained 
when CYP2C9 alone was used 
Wadelius et al. (2007) VKORC1, CYP2C9*2 and *3, PROC, EPHX1, GGCX, 
ORM1-2, age, body weight and drug interactions: 73% 
 
CYP2C9 variants: 15.9% 
Gage et al. (2008) VKORC1 -1639, 3730, CYP2C9*2,*3, body surface area, 
INR, amiodarone, smoker status, age, race, current 
thrombosis: 53-54% 
 
CYP2C9*3: 33% 
IWPC (2009) 
 
Age, height, weight, VKORC1 -1639G>A, CYP2C9*2, 
CYP2C9*3, race, enzyme inducers, amiodarone: 47.0% 
 
Not tested 
Lenzini et al. (2010) Age, INR, VKORC1 -1639 G>A, CYP2C9*2, CYP2C9*3, 
body surface area, target INR, African origin, stroke, diabetes, 
amiodarone, fluvastatin, dose of warfarin in 2, 3 and 4 days 
before INR measurement: 43% 
 
Not stated 
 
 
You et al. (2011) CYP2C9*3, VKORC1 1173C>T, age, weight and vitamin K 
intake: 68% 
 
Not stated 
Teh et al. (2012) Age, CYP2C9*3, VKORC1 -1639G>A and 1173 C>T: 37% 
 
Not stated 
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1.4.3 Clotting factor genes 
Although there were cases of congenital vitamin K-dependant clotting factor deficiency 
(VKCFD) which caused bleeding disorder, the decreased levels of these VKD clotting 
factors are usually not contributed by the mutation of the genes that encode the VKD clotting 
factors themselves (Oldenburg et al., 2000). However, mutation of clotting factors VII-
related genes are reported to decrease the plasmatic clotting factor level in healthy subjects 
(Bernardi et al., 1997). Mutation of clotting factor IX also have been documented to cause 
warfarin hypersensitivity in actual clinical cases (Oldenburg et al., 1997; Kristensen, 2002). 
The occurrence of such clinical cases were however, rare and the correlation study between 
VKD clotting factors alone and warfarin's dose requirement in large cohort did not indicate 
any significant contribution to warfarin dose variability (Aquilante et al., 2006). A 
combination of certain mutations in clotting factors II and VII with CYP2C9*3 genotypic 
data is able to explain 50% of the warfarin dose variability in a study cohort (Shikata et al., 
2004) but the utility of VKD clotting factor mutation were never proven in an actual warfarin 
dosing practice. 
 
1.4.4 Apolipoprotein E gene 
Vitamin K from food is bound to chylomicron in the blood circulation and then taken up by 
the liver. The affinity of chylomicron to be uptaken by the liver is influence by 
apolipoprotein E (APOE) in the chylomicron (Lamon-Fava et al., 1998). However, the gene 
that encodes for APOE is polymorphic, with three APOE variants (ε2, ε3 and ε4) found. 
APOE receptor on the hepatocyte has an increasing affinity to APOE variants in the order of 
ε2<ε3<ε4 (Weintraub et al., 1987). Along with VKORC1, APOE polymorphism may explain 
up to 57% of warfarin dose variability (Sconce et al., 2006). However, univariate analyses of 
APOE usually indicates that APOE is not significantly associated with warfarin's dose 
requirement. Nevertheless, the frequency of the APOE, especially ε4, is too low for it to be 
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clinically practical to help in the determination of warfarin's dose requirement (Kohnke et al., 
2005; Kimmel et al., 2008; Lal et al., 2008; Huang et al., 2011).  
 
1.4.5 Gamma-glutamyl carboxylase gene 
Propeptide VKD clotting factors contain a glutamic acid residue which requires 
carboxylation into γ-carboxyglutamic acid before they can bind to the vascular surface at the 
site of injury. The carboxylation process is catalysed by VKD γ-glutamyl carboxylase 
(Stenflo and Suttie, 1977). The gene that encodes for γ-glutamyl carboxylase (GGCX) is 
polymorphic. Although as many as 37 GGCX SNPs have been discovered in an investigation, 
only a SNP, GGCX 1181T>G, is reported to be marginally associated with warfarin's dose 
requirement and explains only 2% of warfarin dose variability in the study cohort (Rieder et 
al., 2007) indicating that it is not a polymorphism that should be investigated in our study.   
 
1.4.6 Calumenin gene 
VKOR and γ-glutamyl carboxylase are endoplasmic reticulum transmembrane proteins that 
resided close to each other in order to facilitate the transfer of vitamin K between the two 
proteins (Carlisle and Suttie, 1980; Tie et al., 2005). The enzymatic activity of both proteins 
were believed to be regulated by a chaperone protein called calumenin (Wajih et al., 2004). 
Polymorphism of calumenin gene (CALU) lead to overexpression of calumenin and therefore 
reduce the activity of both enzymes (Voora et al., 2010).  However, multiple investigations 
showed that the polymorphism of CALU was just nominally associated with warfarin's dose 
requirement (Wadelius et al., 2007; Voora et al., 2010; Zohir et al., 2014).  
 
  
